CRDF stock icon

Cardiff Oncology
CRDF

$2.44
2.4%
 

About: Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

Employees: 32

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

1,335% more call options, than puts

Call options by funds: $4.67M | Put options by funds: $325K

469% more capital invested

Capital invested by funds: $7.84M [Q4 2023] → $44.6M (+$36.7M) [Q1 2024]

350% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 6

70% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 10

38% more funds holding

Funds holding: 55 [Q4 2023] → 76 (+21) [Q1 2024]

6.87% more ownership

Funds ownership: 11.85% [Q4 2023] → 18.72% (+6.87%) [Q1 2024]

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$7
187%
upside
Avg. target
$11.67
378%
upside
High target
$14
474%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
474%upside
$14
Buy
Reiterated
6 May 2024
HC Wainwright & Co.
Raghuram Selvaraju
474%upside
$14
Buy
Maintained
6 Mar 2024
Piper Sandler
Joseph Catanzaro
187%upside
$7
Overweight
Maintained
1 Mar 2024

Financial journalist opinion

Neutral
GlobeNewsWire
2 months ago
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth – – Enhanced clinical efficacy signal in bev naïve patients in Phase 1b/2 trial is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-line mCRC validating our strategy to evaluate onvansertib in combination with chemo/bev in RAS-mutated first-line mCRC – Therapeutic areas outside of RAS-mutated mCRC – In RAS-wild type mCRC, onvansertib demonstrates antitumor activity in preclinical models as a single agent and in combination with cetuximab, highlighting that onvansertib activity in mCRC can be independent of RAS mutational status – – In SCLC and ovarian cancer, robust preclinical data underscore onvansertib's activity in combination treatments across multiple tumors – SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the presentation of five abstracts at the American Association for Cancer Research (AACR), taking place from April 5-10, 2024, in San Diego, California. In combination, the abstracts underscore the significant potential of the company's lead molecule onvansertib in metastatic colorectal cancer (mCRC) and other cancers.
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study